The Global Generalized Anxiety Disorder Market Size Was Worth Around USD 1.97 Billion In 2024 And Is Predicted To Grow To Around USD 3.86 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 6.31 % From 2025 To 2035.
Generalized anxiety disorder (GAD) refers to a mental health condition that causes people to experience excessive and continuous worries about all aspects of their existence. Individuals suffering from the ailment experience ongoing and irrational fears which they maintain about everything from their work to their health, family and financial matters and other daily activities, even when no valid cause exists for their distress.
This comprehensive market research report provides an in-depth analysis of the Generalized Anxiety Disorder market, with a focused evaluation of industry developments through 2025. The study delivers detailed insights into current market dynamics, emerging trends, growth drivers, competitive landscape, future strategic outlook, and the evolving regulatory key segments.
The Global Generalized Anxiety Disorder Market Report identifies emerging business opportunities while supporting informed strategic and tactical decision-making. Designed for stakeholders operating in a highly competitive and rapidly evolving landscape, this study delivers up-to-date market intelligence essential for tracking performance, mitigating risks, and driving sustainable growth and profitability.
Our expert team is consistently working on updated data and information on the key player's related business processes that value the market for future strategies and predictions
Get Access to a Free Copy of Our Latest Sample Report - https://www.decisionsadvisors.com/request-sample/DAR4466
Market Segmentation:
By Drug Class
- Antidepressants
- Benzodiazepines
- Buspirone
By Therapy
- Interpersonal Therapy
- Behavioural Therapy
- Cognitive Behaviour Therapy
- Mindfulness-Based Cognitive Therapy
Key Players Detail:
In-depth competitive benchmarking analysis of the Generalized Anxiety Disorder Market, covering company market share, innovation strategies, product development, geographic expansion, and strategic partnerships shaping the industry landscape.
- Allergan (AbbVie Inc.)
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly and Company
- GlaxoSmithKline (GSK)
- H. Lundbeck A/S
- Johnson & Johnson
- Merck & Co., Inc.
- MindMed Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Roche Holding AG
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- Others
Key Insights Covered in the Global Generalized Anxiety Disorder Market Size & Industry Forecast Report (2020–2035):
1. Detailed analysis of the Global Generalized Anxiety Disorder Market Size, production capacity, utilization rate, output trends, capital investment patterns, and regulatory landscape, along with comprehensive profiles of leading market players.
2. Thorough assessment of Generalized Anxiety Disorder Market Growth, revenue analysis, historical performance, and forward-looking projections across major regional markets.
3. In-depth Generalized Anxiety Disorder Industry Analysis covering competitive landscape, company market share, pricing trends, and future opportunity mapping.
4. Strategic evaluation of recent developments including mergers & acquisitions, partnerships, collaborations, joint ventures, geographic expansions, and product launches shaping the Generalized Anxiety Disorder Market Share.
5. Comprehensive value chain and supply chain analysis highlighting raw material sourcing, distribution channels, and end-user segmentation.
6. Regional regulatory framework assessment and policy impact analysis influencing the Generalized Anxiety Disorder Industry Forecast across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
7. Coverage of technological advancements, product innovations, R&D investments, automation trends, and digital transformation influencing long-term Global Generalized Anxiety Disorder Market Growth.
Buy this report now:- https://www.decisionsadvisors.com/checkout/select-licence?report_id=DAR4466
Industry Developments:
In February 2026, the NHS launched a landmark national campaign to support millions of adults facing anxiety conditions. The initiative emphasises NHS Talking Therapies, encouraging people to self-refer for treatment rather than struggling alone. New NHS data shows that over 670,000 people accessed talking therapies in 2025, a 12% increase compared to pre-pandemic levels, while 83,000 received employment support through the program—a 20% rise from 2024.
In October 2025, Viatris officially completed its acquisition of Aculys Pharma, strengthening its presence in Japan and the broader Asia-Pacific region. Through this deal, Viatris gains exclusive rights to Pitolisant in Japan and Spydia® (diazepam nasal spray) in Japan and select Asia-Pacific markets.
In December 2024, MindMed officially dosed the first subject in its Phase III clinical trial program for MM120 orally disintegrating tablets (ODT), a proprietary formulation of lysergide D?tartrate (LSD), being developed for Generalized Anxiety Disorder (GAD). This marks a significant step forward in evaluating psychedelic-derived therapies for anxiety disorders, building on positive Phase IIb results that showed strong efficacy and tolerability.
Regional Analysis for Generalized Anxiety Disorder Market:
✫ North America: (U.S., Canada, Mexico)
✫ Europe: (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
✫ Asia-Pacific: (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
✫ South America: (Colombia, Brazil, Argentina, Rest of South America)
✫ Middle East & Africa: (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
⏩ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.
⏩ Top-down and bottom-up approach for regional analysis
⏩ Porter’s five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.
⏩ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market
Insightful inquiry before buying:- https://www.decisionsadvisors.com/request-customization/DAR4466
Frequently asked questions:
➥ What is the market size of the Generalized Anxiety Disorder market?
➥ What is the market growth rate of the Generalized Anxiety Disorder market?
➥ What are the Generalized Anxiety Disorder market opportunities and threats faced by the vendors in the global Generalized Anxiety Disorder Industry?
➥ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?
➥ What focused approach and constraints are holding the Generalized Anxiety Disorder market?
➥ What are the different sales, marketing, and distribution channels in the global industry?
Unlock the full report now! @ https://www.decisionsadvisors.com/reports/generalized-anxiety-disorder-market
About the Decisions Advisors
Decisions Advisors is a comprehensive market research and consulting company that provides actionable insights based on data. We deal with businesses from various industries and deliver a market intelligence, competitive analysis, forecasting, and bespoke consulting. We also conduct bespoke consulting for our clients.
We provides well-supported advice and intelligence on how businesses can operate in a given market and succeed in achieving their goals.
Contact Us:
Company Name: Decision Advisors
Email: sales@sphericalinsights.com
Phone: +1 303 800 4326 (US)
